A full list of affiliations appears at the end of the paper. C OPD is a disease of enormous and growing global burden 1 , ranked third as a global cause of death by the World Health Organization in 2016 (ref. 2 ). Environmental risk factors, predominately cigarette smoking, account for a large fraction of disease risk, but there is considerable variability in COPD susceptibility among individuals with similar smoking exposure. Studies in families and in populations have demonstrated that genetic factors account for a substantial fraction of disease susceptibility. Similarly to other adult-onset complex diseases, common variants are likely to account for the majority of population genetic susceptibility 3,4 . Our previous efforts have identified 22 genome-wide-significant loci 5 . Expanding the number of loci can lead to new insights into disease pathogenesis, not only through discovery of new biology at individual loci 6,7 but also across loci via identification of functional links and specific cell types and phenotypes 5 .
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We identified 82 loci (defined by using 2-Mb windows) at genome-wide significance (P < 5 × 10 −8 ) (Figs. 1 and 2, and Supplementary Figs. 1 and 2 ). Forty-seven of the 82 loci were previously described as genome-wide significant in COPD 5, 11 or lung function [12] [13] [14] [15] [16] [17] [18] [19] [20] (Supplementary Table 2 ), thus leaving 35 new loci (Table 1) at the time of analysis. We then sought to replicate these loci. Given the strong genetic correlation between population-based measures of lung function and COPD, we tested the lead variant at each locus for association with forced expiratory volume in 1 s (FEV 1 ) or FEV 1 /forced vital capacity (FVC) in 79,055 individuals from SpiroMeta 21 (Supplementary Table 3 ). We identified 13 loci-C1orf87, DENND2D, DDX1, SLMAP, BTC, FGF18, CITED2, ITGB8, STN1, ARNTL, SERP2, DTWD1, and ADAMTSL3-that replicated by using a Bonferroni correction for one-sided P value (P < 0.05/35; Table 1 ). Although they did not meet the strict Bonferroni threshold, 14 additional new loci were nominally significant in SpiroMeta (consistent direction of effect and one-sided P < 0.05): ASAP2, EML4, VGLL4, ADCY5, HSPA4, CCDC69, RREB1, ID4, IER3, RFX6, MFHAS1, COL15A1, TEPP, and THRA (Table 1) , and all 82 loci showed a consistent direction of effect in COPD and either FEV 1 or FEV 1 /FVC ratio in SpiroMeta (Table 1 and Supplementary Table 2 ). We note that 9 of our 35 new loci were recently described in a contemporaneous analysis of lung function in UK Biobank 21 . None of the new loci appeared to be explained by cigarette smoking, and variant effect sizes in ever-and never-smokers and including and excluding selfreported asthmatics were similar (Supplementary Note). In addition, we found no significant differences in variant effects by sex (Supplementary Note). Including all 82 genome-wide-significant variants, we explained up to 7.0% of the phenotypic variance on the liability scale, using a 10% prevalence for COPD, acknowledging that these effects are likely to be overestimated in the discovery sample. This represents up to a 48% increase in COPD phenotypic variance explained by genetic loci, as compared with the 4.7% explained by the 22 loci reported in a recent GWAS of COPD 5 .
Identification of secondary association signals. We used approximate conditional and joint analysis 22 to find secondary signals at each of the 82 genome-wide-significant loci. We found 82 secondary signals at 50 loci, thus resulting in a total of 164 independent associations at 82 loci ( Supplementary Table 4 ). Of the 50 loci containing secondary associations, 33 were at loci previously described for COPD or lung function, and 6 were at Bonferroni-replicated new loci. Of the 82 secondary associations, 20 reached genome-wide significance (P < 5 × 10 −8 ) ( Supplementary Table 4 ). Of the 61 new (not previously described in COPD or lung function) independent associations, 21 reached a region-wise Bonferroni-corrected significance threshold (one-sided P < 0.05/new independent association(s) at each locus) in unconditioned associations from SpiroMeta (Methods and Supplementary Table 4 ).
Tissues and specific cell types. In determining the tissue in which COPD genetic variants function to increase COPD risk, the lung is the obvious tissue to consider. However, COPD is a systemic disease 23, 24 , and within the lung, the cell types collectively contributing to disease pathogenesis are largely unknown. Furthermore, available databases include nonlung cell types, such as smooth muscle in the gastrointestinal (GI) tract, that are relevant to lung biology. To identify putative causal tissues and cell types, we assessed heritability enrichment by using integrated genome annotations at the single-tissue level 25 and tissue-specific epigenomic marks 26 . Lung tissue showed the highest enrichment (enrichment = 9.25, P = 1.36 × 10 −9 ), as previously described, although significant enrichment was also seen in the heart (enrichment = 6.85, P = 3.83 × 10 −8 ) and the GI tract (enrichment = 5.53, P = 6.45 × 10 −11 ). In an analysis of enriched epigenomic marks, the most significant enrichment was in fetal lung and GI smooth muscle DNase-hypersensitivity sites (DHSs) (P = 6.75 × 10 −8 ) and H3K4me1 (P = 7.31 × 10 −7 ) (Supplementary Table 5 ). To identify the source of association within lung tissue, we tested for heritability enrichment by using single-cell chromatin accessibility 27 (ATAC-seq) and gene expression (RNA-seq) data from human 28, 29 and mouse 30 lung (Supplementary Table 5 ). Using LD score regression in mouse ATAC-seq data, we found enrichment of chromatin accessibility in several cell types, including endothelial cells (most significant) as well as type 1 and type 2 alveolar cells (with the latter among the tissues with the highest fold enrichment; Supplementary  Table 5b ). Results from using LD score regression 31 or SNPsea 32 on single-cell RNA-seq data varied, with nominal P values for genes expressed in type 2 alveolar cells, basal-like cells, club cells, fibroblasts, and smooth muscle cells ( Supplementary Table 5c ,d).
Fine-mapping of associated loci. To identify the most likely causal variants at each locus, we performed fine-mapping using Bayesian credible sets 33 . Including 160 potential primary and secondary association signals (excluding four variants in the major histocompatibility complex (MHC) region), 61 independent signals had a 99%-credible set with fewer than 50 variants; 34 signals had credible sets with fewer than 20 variants ( Supplementary Fig. 3 ). Eighteen loci had a single variant with a posterior probability of driving association (PPA) greater than 60%, including the NPNT (4q24) locus, where the association could be fine-mapped to a single intronic variant, rs34712979 (NC_000004.11:g.106819053 G>A; Supplementary Note and Supplementary Table 6 ). Most sets included variants that overlapped genic enhancers in lung-related cell types (for example, fetal lung fibroblasts, fetal lung, and adult lung fibroblasts) and were predicted to alter transcription-factorbinding motifs ( Supplementary Table 6 ). Of the 61 credible sets with fewer than 50 variants, 8 sets contained at least one deleterious variant. These deleterious variants included (i) missense variants affecting TNS1, RIN3, ADGRG6, ADAM19, ATP13A2, BTC, and CRLF3 and (ii) a splice donor variant affecting a long intergenic noncoding RNA (lincRNA), AP003059.2.
Candidate target genes. In most cases, the closest gene to a lead SNP will not be the gene most likely to be the causal or effector gene for disease-associated variants [34] [35] [36] . Thus, to identify the potential effector ('target') genes underlying the genetic associations, we integrated additional molecular information including gene expression, gene regulation (open chromatin and methylation data), chromatin 
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interaction, co-regulation of gene expression with gene sets, and coding variant data ( Fig. 3 and Methods). At the 82 associated loci, 472 genes within 1 Mb of the top associated variants were implicated by analysis of at least one dataset; 106 genes were implicated by lung gene expression 37, 38 , and an additional 50 genes were implicated by two or more other datasets (methylation 39 , chromatin interaction 40 , open chromatin regions 41 , similarity in gene sets 42 , or deleterious coding variants 43 ; Fig. 3 ), for a total of 156 genes meeting more stringent criteria. Excluding loci in the MHC region, the median number of potentially implicated genes per locus was four, with a maximum of 17 genes (7q22.1 and 17q21.1). The median distance of the implicated genes to the top associated variants was 346 kb. Of the 82 loci, 60 (73%) included the nearest gene among the implicated genes. We identified 20 genes with supportive evidence from exome-sequencing data. Two genes (ADAM19 and ADAMTSL3) were each implicated by five datasets ( Fig. 3) , and another two (EML4 and RIN3) were implicated by four datasets. A summary of all genes implicated by using these approaches is included in Supplementary Table 7 .
Associated pathways. To gain further functional insight into the associated genetic loci, we performed gene-set enrichment analysis by using DEPICT 42 . Among the 165 enriched gene sets at a falsediscovery rate (FDR) <5%, 44% were related to the developmental process term, with a nominal P value for lung development of 1.02 × 10 −6 ; significant subterms included lung alveolus development (P = 0.0003) and lung morphogenesis (P = 0.0005). We also found enrichment of extracellular-matrix-related pathways, including laminin binding, integrin binding, mesenchyme development, cell-matrix adhesion, and actin filament bundles. Additional pathways of note included histone deacetylase binding, the Wnt-receptor signaling pathway, SMAD binding, the MAPK cascade, and the transmembrane receptor protein serine/threonine kinase signaling pathway. Full enrichment analysis results, including the top genes for each DEPICT gene set, are shown in Supplementary Table 8 .
Identification of drug targets. GWAS is also useful for identifying drug targets at either the individual gene 18, 44, 45 or genome-wide 46, 47 level. Of the 472 candidate target genes, 59 genes were targeted by at least one approved or in-development drug 48 , for a total of 427 drugs with 134 different modes of action ( Supplementary Table 9 ). Druggable targets at new loci for COPD and lung function included ABHD6, CDKL2, GSTO2, KCNC4, PDHB, SLK, and TRPM7. We also identified drugs for repurposing in COPD by using transcriptome-wide associations and drug-induced gene expression signatures 49 (Supplementary Note).
Phenotypic effects of COPD-associated variants.
To characterize the phenotypic effects of the 82 genome-wide-significant loci, we performed a phenome-wide association analysis within the deeply phenotyped COPDGene study (Methods). We looked for common patterns of phenotype associations for the 82 loci by using hierarchical clustering across scaled z scores of phenotype-variant associations. We identified two clusters of variants differentially associated with two sets of phenotypes ( Supplementary Fig. 4 ). Because these two variant-phenotype clusters appeared to be driven by computed tomography (CT) imaging features, we repeated variant clustering but limited analysis to quantitative CT imaging features. We again found two clusters of variants, differentiated by association with quantitative emphysema, emphysema distribution, gas trapping, and airway phenotypes (Fig. 4a ). Additionally, we evaluated the association of the 82 genome-wide-significant variants in a prior GWAS of emphysema and airway quantitative CT features 50 ( Supplementary Table 10 ).
We also examined all genome-wide-significant loci in the NHGRI-EBI GWAS Catalog 51 ( Supplementary Fig. 5 and Supplementary  Table 11 ) and looked for trait-associated variants in LD (r 2 > 0.2) with our lead COPD-associated variants. Many variants were associated with anthropometric measures including height and body mass index (BMI), measurements on blood cells (red and white blood cells), and cancers. COPD is well known to have many common comorbidities, such as coronary artery disease (CAD), type 2 diabetes mellitus (T2D), osteoporosis, and lung cancer. Of these diseases and 13 additional traits, we confirmed previously reported overall genetic correlation (by using LD score regression 52 ) of COPD with lung function, asthma, and height and found evidence of a modest Articles Nature GeNetics correlation between COPD and lung cancer (Supplementary Note). However, at individual loci and using a more stringent LD threshold (r 2 > 0.6), we found evidence of shared risk factors for these comorbid diseases and COPD, including a genome-wide-significant variant near PABPC4 associated with T2D, four variants associated with CAD (near CFDP1, DMWD, STN1, and TNS1), and a variant near SPPL2C associated with bone density (Fig. 4b ).
Overlapping loci with asthma and pulmonary fibrosis. On the basis of our previous identification of genetic overlap of COPD with asthma, and COPD with pulmonary fibrosis, we examined loci for overlap specifically with these two diseases. In asthma, we noted r 2 >0.2 with one of our variants and previously reported variants at ID2, ZBTB38, C5orf56, MICA, AGER, HLA-DQB1, ITGB8, CLEC16A, and THRA. In pulmonary fibrosis, in addition to our previously described overlap at FAM13A, DSP, and 17q21, we noted overlapping associations at ZKSCAN1 and STN1 ( Supplementary  Table 12 ). To more closely examine overlap, we applied a Bayesian method (gwas-pw 53 ) to COPD associations from our current GWAS and previous GWAS results for asthma (limited to those of European ancestry) and pulmonary fibrosis 54, 55 . To mitigate the effects of including individuals with asthma among our COPD cases, we performed analysis for overlap with asthma after removing self-reported individuals with asthma from UK Biobank for this analysis (Methods). We identified 14 shared genome segments (posterior probability >70%), 9 for asthma and 5 for pulmonary fibrosis ( Fig. 4c and Supplementary Table 13 ). In addition to the three segments shared with pulmonary fibrosis identified in the previous study 5 (FAM13A, DSP, and the 17q21 locus-here nearest CRHR1), we identified two new segments including loci near ZKSCAN1 and STN1 (formerly known as OBFC1). Shared variants for COPD and pulmonary fibrosis all had opposite directions of effect in the two diseases (that is, increasing risk for COPD but protective for pulmonary fibrosis). In asthma, we identified five shared segments in the 6p21-22 region, as well as the segments containing ADAM19, ARMC2, ELAVL2, and STAT6. With the exception of the segment with STAT6, overlapping variants showed the same direction of effect.
Discussion
Genetic factors have an important role in COPD susceptibility. We examined genetic risk of COPD in a GWAS of 35,735 cases and 222,076 controls. We identified 82 genome-wide-significant loci for COPD, of which 47 were previously identified in GWAS of COPD or population-based measures of lung function. Of the 35 loci not previously described at the time of analysis, 13 replicated in an independent study of population-based lung function. We used several data sources to attempt to assign causal genes at each locus, identifying 156 genes at the 82 loci that were supported by either gene expression or a combination of at least two other data sources. Our results identify specific genes, cell types, and biological pathways for targeted study and also suggest a genetic basis for the clinical heterogeneity seen in COPD.
Our study supports a role for early life events in the risk of COPD. Gene-set enrichment analysis identified developmental pathways both specific to the lung (for example, lung morphogenesis and lung alveolar development) and related to the lung (for example, the canonical Wnt receptor 56, 57 and MAPK-ERK and nerve growth factor receptor signaling pathways). We also confirmed enrichment of heritability for epigenomic marks in the fetal lung. Our findings are consistent with epidemiological studies demonstrating that a substantial portion of the risk for COPD may develop in early a 82 Articles Nature GeNetics life: genetic variants may set initial lung function 58 and patterns of growth [58] [59] [60] . Although further work will be needed to confirm the causal variants and genes affected by our variants, testing the role of these genes in lung-development-relevant mouse or ex vivo models-for example, determining whether perturbation of these genes changes proliferation and differentiation of lung epithelial progenitors in induced pluripotent stem cell (iPSC)-derived alveolar type 2 lung cells 44 -could provide experimental evidence for the role of these genes in early life susceptibility. Ultimately, the goal of this work would be to identify targets for or subsets of high-risk individuals early in the disease course or molecular candidates that may affect lung repair and regeneration 61 . Apart from genes related to lung development, our analyses highlighted several genes and pathways already of interest in COPD therapy (including the COPD target/therapy relationships exemplified by CHRM3/acetylcholine receptor inhibitors and the MAPK pathway/p38 inhibitors)-supporting the role of genetic analyses in finding therapeutic targets 18, 62 -and newer genes that may inform future functional studies. We identified IL17RD (encoding IL-17 receptor D) as a potential effector gene at the 3p14 locus. Numerous studies have examined the role of IL-17A in COPD 63 , and IL17RD can differentially regulate pathways employed by IL-17A 64 . CHIA (chitinase acidic) at 1p13.3, which encodes a protein that degrades chitin 65 , exhibits lung-specific expression 66, 67 . CHIA variants have been associated with FEV 1 68 , asthma [69] [70] [71] [72] , and acid mammalian chitinase activity 71, 73 . We identified several potential effector genes related to extracellular matrix, cell adhesion, cell-cell interactions, and elastin-associated microfibrils [74] [75] [76] , some of which have previously been identified in studies of lung function 15 . These include integrin family members that mediate cell-matrix communication (for example, ITGA1, ITGA2, and ITGA8 [77] [78] [79] ), an integrin-ligandencoding gene (NPNT 80 ), and genes encoding matrix proteins (for example, MFAP2 and ADAMTSL3). ADAMTSL3 has a role in cell-matrix interactions related to assembly of fibrillin and microfibril biogenesis [81] [82] [83] , and of our candidate effector genes, it was supported by the greatest number of bioinformatic analyses. Recombinant forms of other ADAMTS-like proteins have shown evidence in experiments of promoting and enhancing fibrillin and microfibril deposition and assembly 84, 85 . ADAMTSL3 may have a role in preventing emphysematous destruction of lung tissue by ADAMTS in COPD.
In addition to identifying the effector gene for a variant, knowing the effector cell type is critical for functional studies. We identified an overall enrichment of epigenomic marks in lung tissue and GI smooth muscle (also identified in studies of lung function 16 ); respiratory smooth muscle was absent from the analyzed datasets. We also performed analyses of single-cell data in an attempt to identify the specific lung cell types in which our top variants are potentially functioning. We found evidence for enrichment of several cell types, including but not limited to endothelial cells, alveolar type 2 cells, and basal-like cells. Each of these cell types has been postulated to have a role in the development of COPD [86] [87] [88] , and our data are consistent with the likely heterogeneity of lung cell types contributing to COPD susceptibility. The lung comprises at least 40 different resident cell types 89 , most of which were not distinctly represented in these datasets. Thus, while our findings support the investigation of specific cell types for further functional studies, they also highlight the need for profiling of lung-relevant cell types and locus-specific analyses.
Characterization of functional variant effects could lead to better disease subtyping and more targeted therapy for COPD. Cluster analysis on hundreds of COPD-associated features in the more extensively phenotyped COPDGene cohort showed heterogeneous effects of genetic variants on COPD-related phenotypes, including CT measurements of airway abnormalities and emphysemawell-described sources of heterogeneity in COPD [90] [91] [92] . Analyzing   ARMC2  CITED2  CHRM3  LRMDA  ITGA1  MICAL3  SLC30A10  GLIS3  MECOM  FAM13A  THSD4  HTR4  RBMS3  ARNTL  PABPC4  TNS1  STN1  TWIST2  FGF18   HHIP  CHRNA3  ASTN2  MFAP2  ADGRG6  AGER  ZKSCAN1  ADAMTSL3  BTC  ITGB8  SNRPF  NPNT  CACNA2D3  CCDC91 Articles Nature GeNetics hundreds of diseases and traits in the GWAS Catalog, we identified overlapping associations with various diseases and traits in multiple organ systems, including comorbidities such as CAD, bone mineral density, and T2D. The COPD-associated PABPC4 locus was associated with T2D 93 and C-reactive protein (CRP) levels 94 . Although a causal gene in this locus and its contribution to COPD are unknown, the association of this locus with T2D may suggest a shared disease pathway and drug targets. In sum, the identification of variable associations for COPD risk loci with subphenotypes and other diseases 95, 96 may have potential for more nuanced approaches to therapy for COPD. Overall, our phenotype, gene, and pathway analyses illustrate the utility of both searching for enrichment of genetic signals overall and performing more detailed identification of the effects of individual variants or groups of variants. We performed additional specific analysis in two diseases that overlap with COPD, asthma and pulmonary fibrosis. Genomewide genetic correlation of COPD with asthma has previously been described 5 , but our analysis is, to our knowledge, the first to identify specific genetic segments shared by asthma and COPD. While the effects at most of these shared segments were concordant in direction, one of the segments of particular interest near STAT6 had opposite directions of effect in the two diseases. STAT6 has a role in helper T cell type 2-dependent inflammation and is activated by IL-4 and IL-13 97 . IL-13 in turn has been found at increased levels in asthmatic airways 98 but at decreased levels in severe emphysema 99 . In pulmonary fibrosis, variants at all overlapping loci have an opposite direction of effect in comparison to COPD 5 . This observation raises the possibility that specific therapies for one disease could increase the risk for the other disease, which may be worth evaluating in treatment trials. The reasons why genetic effects are divergent in COPD and fibrosis are unclear, but these identified opposite effects could point to molecular switches that influence why some smokers develop emphysema whereas others develop pulmonary fibrosis. Although pulmonary fibrosis is an uncommon disease and was specifically excluded in several of our COPD case-control cohorts, interstitial lung abnormalities are increasingly being recognized as a potential precursor to fibrosis, and an inverse relationship between these abnormalities and emphysema has previously been identified 100 . Mechanistically, some have hypothesized that divergent derangement of Wnt and Notch signaling pathways 101 and mesenchymal cell fate 102 may be responsible for the distinct development of these two diseases. We also describe an overlapping region at the STN1 (previously known as OBFC1) locus. STN1 has a role in telomere maintenance 103 ; shortened telomeres have been observed in both COPD and idiopathic pulmonary fibrosis (IPF) 104, 105 , and rare genetic variants in the telomerase pathway have been implicated in both pulmonary fibrosis and emphysema-though with a concordant direction of genetic risk effects in both diseases 106 .
Although our study is a large GWAS of COPD, individuals meeting our criteria for COPD in UK Biobank may be different from those in other studies, especially with respect to smoking history. We used the same definition of COPD as in our previous analysis 5 , which included nonsmokers. Our use of prebronchodilator spirometry to define COPD (allowing us to maximize sample size) as well as population-based measures of lung function for replication could bias our findings against variants that are only associated with more severe forms of COPD. We did not exclude other causes of airway obstruction such as asthma, noting that asthma frequently overlaps with and is misdiagnosed in COPD 107 . We performed several additional analyses to determine whether our findings were driven by or markedly different as a result of smoking status, asthma, or use of pre-instead of postbronchodilator spirometry to define COPD. The results of these additional analyses did not indicate a substantial effect of these factors on our overall findings and, together with prior analyses 5, 16 , suggest that bias due to these factors is likely to be small. However, our study was not designed to identify differences between subgroups, and we cannot rule out a role for studying more severe disease or disease subtypes. We note that the alpha-1 antitrypsin locus (SERPINA1) has been identified as genome-wide significant in smaller studies of emphysema and in smokers with severe COPD 108 . In the current study, the PiZ allele (NC_000014.8:g.94844947C>T, rs28929470) was associated with P = 2.2 × 10 −5 by using moderate to severe cases (FEV 1 <80% predicted) and with a smaller P value (1.4 × 10 −6 ) in severe cases (FEV 1 <50% predicted) despite a smaller sample size, a phenomenon that we have previously described 11 . Thus, despite the strong overlap of COPD with quantitative spirometry measures, new loci may be identified through studies of sufficiently large subsets of patients with COPD and with more specific and homogeneous COPD phenotypes. Given the suggestive evidence for replication using a related (but not identical) phenotype for additional new loci beyond the 13 meeting a Bonferroni-corrected threshold for significance, we chose to include all loci significant in discovery in subsequent analyses, recognizing that we probably included some false-positive associations. Our study focused on relatively common variants, predominantly in individuals of European ancestry; more detailed studies of rare variants, the human leukocyte antigen (HLA) regions, and other ancestry groups are warranted, but broader multiancestry analyses are limited by the number of cases in currently available cohorts. Although COPD sex differences have been reported 109 , we did not identify significant sex-specific differences in the effect sizes of the 82 top variants. Future studies including more subjects and methodological advances may be needed to elucidate this.
The global burden of COPD is increasing. Our work found a substantial number of new loci for COPD and used multiple lines of supportive evidence to identify potential genes and pathways for both existing and new loci. Further investigation of the genetic overlap of COPD with other respiratory diseases and the phenotypic effects of top loci found new shared loci for asthma and IPF and suggested heterogeneity across COPD-associated loci. Together, these insights provide multiple new avenues for investigation of the underlying biology and potential therapeutics in this deadly disease.
URLs. HGNC database of human gene names, https://www.genenames.org/; Drug Repurposing Hub, https://clue.io/repurposing/; The Query, https://clue.io/query/; Human Genome Region MHC by the Genome Reference Consortium, https://www.ncbi.nlm.nih. gov/grc/human/regions/MHC?asm=GRCh37.p13; EMBL-EBI GWAS Catalog, https://www.ebi.ac.uk/gwas/; LungMAP, https:// www.lungmap.net/.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
We derived various metrics on spirometry quality control using R. Software for genotype imputation: IMPUTE2 (ARIC, CHS AA, KARE, MESA, SPIROMICS), minimac (CHS EUR, COPDGene, ECLIPSE, FHS, LifeLines, NETT-NAS, GenKOLS), MaCH (COPDGene, ECLIPSE, FHS, NETT-NAS, GenKOLS), and Michigan Imputation Server (eQTL).
